ABSTRACT BACKGROUND: Opiate abuse and overdose reached epidemic levels in the United States. However, despite significant advances in animal and in vitro models, little knowledge has been directly accrued regarding the neurobiology of the opiate-addicted human brain. METHODS: We used postmortem human brain specimens from a homogeneous European Caucasian population of heroin users for transcriptional and epigenetic profiling, as well as direct assessment of chromatin accessibility in the striatum, a brain region central to reward and emotion. A rat heroin self-administration model was used to obtain translational molecular and behavioral insights. RESULTS: Our transcriptome approach revealed marked impairments related to glutamatergic neurotransmission and chromatin remodeling in the human striatum. A series of biochemical experiments tracked the specific location of the epigenetic disturbances to hyperacetylation of lysine 27 of histone H3, showing dynamic correlations with heroin use history and acute opiate toxicology. Targeted investigation of GRIA1, a glutamatergic gene implicated in drug-seeking behavior, verified the increased enrichment of lysine-27 acetylated histone H3 at discrete loci, accompanied by enhanced chromatin accessibility at hyperacetylated regions in the gene body. Analogous epigenetic impairments were detected in the striatum of heroin self-administering rats. Using this translational model, we showed that bromodomain inhibitor JQ1, which blocks the functional readout of acetylated lysines, reduced heroin self-administration and cue-induced drug-seeking behavior. CONCLUSIONS: Overall, our data suggest that heroin-related histone H3 hyperacetylation contributes to glutamatergic transcriptional changes that underlie addiction behavior and identify JQ1 as a promising candidate for targeted clinical interventions in heroin use disorder. With an unprecedented 80% increase in the number of heroinabusing or -dependent individuals over the past few years, opiates are currently the second most prevalent class of abused drugs in the United States, and opiate overdose is now the leading cause of death among drug users (1-3). The fact that heroin is one of the most addictive drugs, along with the increasing availability of both heroin and prescription opioids (4-8), has led to an increasing burden on society (9) and emphasizes the critical need for greater efforts to expand the understanding of neurobiological underpinnings of heroin use disorder to develop new medication strategies.
With an unprecedented 80% increase in the number of heroinabusing or -dependent individuals over the past few years, opiates are currently the second most prevalent class of abused drugs in the United States, and opiate overdose is now the leading cause of death among drug users (1) (2) (3) . The fact that heroin is one of the most addictive drugs, along with the increasing availability of both heroin and prescription opioids (4) (5) (6) (7) (8) , has led to an increasing burden on society (9) and emphasizes the critical need for greater efforts to expand the understanding of neurobiological underpinnings of heroin use disorder to develop new medication strategies.
The striatum is a central anatomical hub for the neurobiological actions of heroin because it integrates information from midbrain, cortical, and thalamic circuits to regulate reward and cognitive function (10) . As with other drugs of abuse, the long-term repeated pattern of heroin-seeking and heroin-taking behaviors leads to marked alterations of striatal plasticity. Despite a significant body of research in animal and in vitro models demonstrating drug-induced synaptic plasticity, there is still a significant dearth of knowledge accrued about the molecular neurobiology of the human brain in substance use disorders. Shedding light about neural systems directly relevant to the human condition also allows the possibility to provide critical "reverse translation" perspectives to better guide mechanistic studies in animal models.
To that end, we focused on the striatum of human heroin abusers in a series of molecular investigations. Based on converging evidence from postmortem human molecular studies, as well as a translational rodent self-administration model, we identified specific epigenetic impairments related to histone H3 acetylation that contribute to transcriptional changes underlying heroin-induced plasticity at glutamatergic synapses of the striatum. Moreover, we show that by blocking the functional readout of heroin-related histone H3 hyperacetylation, we were able to reverse heroin self-administration and drug-seeking behavior in vivo. Our findings indicate that targeting heroin-induced histone acetylation in the striatum has a tremendous potential to contribute to the development of novel therapeutic approaches in opiate use disorders.
METHODS AND MATERIALS Human Heroin Abuse Population
Human brains from apparent heroin overdose and normal control Caucasian subjects (determined by self-report and ancestral informative marker analysis) without head trauma were collected at autopsy within 24 hours at the Department of Forensic and Insurance Medicine, Semmelweis University, Hungary, as described previously (11) . Cause of death was determined by the forensic pathologist performing the autopsy. Inclusion criteria for the heroin group were documented history of heroin use and/or positive toxicology at the time of death and physical evidence of intravenous drug use (needle tracks), whereas multidrug users (as determined by history and blood/urine toxicology at autopsy), subjects receiving methadone/buprenorphine treatment, and subjects with comorbid psychiatric diagnoses were excluded. For the control group, inclusion criteria were negative toxicology, no history or physical evidence of opiate or other drug use, and no documented psychiatric disorders. Table S1 in Supplement 1 provides detailed demographic information including cause of death for each subject. Table S2 in Supplement 1 shows a summary description of the populations used for each molecular experiment. Univariate correlations for demographic variables (e.g., age, pH) were explored and significant variables were included in the final model. Ventral and dorsal striatal (putamen) tissue punches were obtained at the level of the nucleus accumbens (NAc) ( Figure S1 in Supplement 1).
Rodent Heroin Self-administration
Adult male Long-Evans rats underwent jugular vein catheterization and trained to self-administer heroin in soundattenuating boxes (MED Associates Inc., St. Albans, VT) with two levers; depression of one (active lever) delivered 30 μg/kg of heroin under a fixed-ratio 1 (FR1) reinforcement schedule, whereas depression of the other (inactive lever) had no programmed consequences (see Supplemental Methods in Supplement 1 for details). Each session was 3 hours. Following seven FR1 sessions, animals underwent four additional FR5 sessions. For the JQ1 experiments, only rats that differentiated between active and inactive levers and showed an escalation of correct responses under the FR5 schedule were studied. Guide cannulae (C317G-SPC, cut 4 mm below pedestal; Plastics One, Roanoke, VA) for JQ1 administration were inserted into the rostral dorsal striatum (101 angle from midline relative to bregma: anteroposterior 1 1.7 mm, mediolateral 1 3.5 mm; dorsoventral 22.0 mm; Figure S2 in Supplement 1). After establishing a postsurgery baseline (average of 2 days), 2 μL of 20 μmol/L of JQ1 was injected into animals 5 minutes before heroin self-administration and before a nonreinforced cue-induced drug-seeking reinstatement session (1 hour). All animal testing was carried out using a counterbalanced experimental design at a similar time of the day.
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RESULTS

Long-term Heroin Use Leads to Striatal Transcriptional Impairments Related to Glutamatergic Neurotransmission and Histone Acetylation
To better understand the transcriptional impairments that underlie heroin-induced synaptic plasticity in the striatum, we first examined existing data (12) from transcriptional profiling of the ventral striatum (NAc) of postmortem human heroin users and matching control subjects (see Tables S1 and S2 in Supplement 1 for demographic information). Using the Affymetrix HG-U133A microarray data (normalized with the GeneChip [Affymetrix, Santa Clara, CA] robust multiarray averaging method for microarray normalization and corrected for covariates), we identified 2132 differentially expressed genes (Table S3 in Supplement 1; the raw data have been deposited in Gene Expression Omnibus). Gene ontology analysis (Database for Annotation, Visualization and Integrated Discovery [DAVID], version 6.7) of this dataset showed enrichment of genes related to synaptic function and glutamatergic neurotransmission (Table S4 in Supplement 1). We next applied weighted gene coexpression network analysis (WGCNA), which clusters genes into modules based on correlations among their expression pattern. In line with the gene ontology analysis, the top WGCNA dysregulated module (turquoise; p , .001 at false discovery rate , 0.1%) in heroin subjects corresponded to genes related to synaptic neurotransmission ( Figure 1A) . Furthermore, an independent network analysis approach using the MetaCore software (Thomson Reuters, New York, NY) that is based on connections reported in the literature also showed networks enriched for genes related to glutamatergic neurotransmission ( Figure 1B) .
Intriguingly, we observed a predominant upregulation of glutamate-related genes, with 64 of the 87 significantly altered glutamatergic genes being expressed at higher levels in heroin abusers (Table S5 in Supplement 1). We validated the microarray findings using NanoString and confirmed the overexpression of several glutamatergic markers, including GRIA1 (glutamate receptor, ionotropic, alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid [AMPA] 1), GRIA3 (glutamate receptor, ionotropic, AMPA 3), and GRM5 (glutamate receptor, metabotropic 5) (see Figure 1C for microarray and Figure 1E for NanoString).
In addition to glutamatergic neurotransmission, the microarray analysis revealed significant upregulation of several histone acetyltransferases in heroin abusers, including NCOA1 Histone Acetylation Impairments in Human Heroin Users (nuclear receptor coactivator 1), NCOA3 (nuclear receptor coactivator 3), and KAT6B (lysine acetyltransferase 6b) ( Figure 1D ). The increased expression of NCOA1 was also confirmed using NanoString in an additional cohort of heroin users ( Figure 1F ). Furthermore, we observed significant downregulation of HDAC5 (histone deacetylase 5) ( Figure 1D ), which together with the NCOA alterations predicted increased levels of histone H3 acetylation in the striatum of long-term heroin users.
Global Perturbations of Chromatin Remodeling in the Dorsal Striatum of Long-term Heroin Users Relate to Drug Use History and Acute Morphine Toxicology
To determine whether epigenetic alterations were also evident on the protein level, we focused on biochemical studies of the dorsal striatum (putamen) due to the larger availability of this striatal region for the assays that required significant amounts of tissue and the strong role of this subregion in compulsive habitual behavior that characterizes the addicted state (13) . The global state of posttranslational modifications of histone H3 proteins was first investigated by Western blotting using antibodies specific to activating marks acetylated histone H3 (pan-AcH3), trimethyl-lysine 4 histone H3, and trimethyl-lysine 36 histone H3, as well as repressive marks trimethyl-lysine 9 histone H3, dimethyl-lysine 9 histone H3, and trimethyl-lysine 27 histone H3. Although no group differences were observed for any of the marks investigated, we found an intriguing and statistically significant positive correlation between pan-AcH3 and years of previous drug use (r 5 .57, p 5 .0268; Figure 2A ). NCOA1 messenger RNA levels were also positively correlated to years of use (r 5 .63, p 5 .0163). In addition, pan-AcH3 was negatively correlated with urine morphine levels (r 5 2.47, p 5 .0144; Figure 2B ), whereas trimethyl-lysine 27 histone H3 showed a positive correlation (r 5 .44, p 5 .0182) to urine morphine. Together, these findings suggest that although long-term heroin use leads to histone H3 hyperacetylation, acute exposure to the drug facilitates the formation of a more repressed state of chromatin in the dorsal striatum.
It is well established that posttranslational modifications of histones can have different outcomes based on the lysine residues affected, such that amino acid resolution is necessary to reliably interpret epigenetic states. Therefore, we sought to determine which specific lysine residue(s) were hyperacetylated in the dorsal striatum of human heroin users that contributed to the pan-AcH3 observations. To this end, we performed a series of Western blots using antibodies specifically targeting acetylated lysine residues at positions K9, K14, K18, K23, K27, K36, and K56 within the N-terminal tail of histone H3. Interestingly, H3K23 was the only residue that showed differential acetylation in heroin users versus controls (fold change 5 1.93, p 5 .0356; Figure S3A in Supplement 1). However, lysine-23 acetylated histone H3 (H3K23ac) did not correlate well with pan-AcH3 and was not affected by drug history and toxicology. In contrast, despite the lack of an overall significant group difference ( Figure S3B in Supplement 1), lysine-27 acetylated histone H3 (H3K27ac) correlated strongly with pan-AcH3 (r 5 .62, p 5 .0001) and reproduced the correlations with years of heroin use (r 5 .70, p 5 .0381; Figure 2C ) and urine morphine (r 5 2.47, p 5 .0241; Figure 2D ). Taken together, these data suggest that the heroin-induced hyperacetylation occurs in a specific region of histone H3, in the area around lysine residues K23 and K27.
Long-term Heroin Use Leads to Histone H3 Hyperacetylation and Increased Chromatin Accessibility at Glutamatergic Genes
The histone H3 hyperacetylation observed in long-term heroin users suggested a more open state of chromatin conducive to increased transcriptional activity, in line with the gene expression impairments described in Figure 1 . Thus, we hypothesized that histone H3 hyperacetylation might be an underlying mechanism contributing to enhanced glutamatergic gene expression in heroin users. We focused on GRIA1 because this gene encodes the GRIA1 AMPA receptor subunit that is highly implicated in drug addiction behavior and synaptic plasticity (14) (15) (16) (17) . Interestingly, both pan-AcH3 (r = .41, p = .0316; Figure 3A ) and H3K27ac (r 5 .50, p 5 .0143; Figure 3B ) showed a positive correlation with GRIA1 expression in heroin users, but not in control subjects.
To assess heroin-related histone H3 hyperacetylation specifically at glutamate-related genes, we performed pan-AcH3 and H3K27ac chromatin immunoprecipitation (ChIP) experiments coupled with real-time PCR targeting the GRIA1 gene. The pan-AcH3 ChIP ( Figure 3C ) revealed significant hyperacetylation 3 kb upstream and 2 kb downstream from the transcription start site (TSS). For H3K27ac, several other conserved regions within the gene body of GRIA1 were assayed to obtain better resolution of the acetylation landscape. H3K27ac enrichment was significantly increased 2 kb downstream from the TSS and at another distant intragenic site located 165 kb downstream from the TSS ( Figure 3D ). In addition, gene body acetylation of GRIA1 2 kb downstream of TSS was negatively correlated with blood morphine levels (r 5 2.42, p 5 .0221), in line with the proposed repressive nature of acute morphine toxicology on histone acetylation and gene expression. 
Histone Acetylation Impairments in Human Heroin Users
To determine whether the observed histone hyperacetylation translates into a more open state of chromatin in longterm heroin users, we next studied chromatin accessibility directly using the assay for ATAC-seq. ATAC-seq was performed in fluorescence-activated cell sorting-sorted neuronal (NeuN positive) cell populations from the dorsal striatum of human heroin users and controls. Emphasizing the strength of this approach, we were able to reliably demonstrate open chromatin in NeuN-positive cells at genes expressed specifically in neurons (e.g., CAMK2A, Figure S4A in Supplement 1), whereas glial markers (e.g., OLIG2) were only accessible in the NeuN-negative cell population ( Figure S4B in Supplement 1). Using this platform, we assayed chromatin state along the GRIA1 gene in regions corresponding to the PCR products of our ChIP PCR primers. Two of the regions investigated with ChIP overlapped with ATAC peaks. Strikingly, chromatin accessibility was significantly increased in heroin users in the same region located 165 kb downstream from the TSS (Figure 3F ), where H3K27ac enrichment was also significantly higher ( Figure 3D ). Consistently, chromatin accessibility was not affected by heroin in another genomic location in which H3K27ac enrichment was not induced ( Figure 3E ). Taken together, these results suggest that histone H3 hyperacetylation related to long-term heroin use leads to a more open state of chromatin along genes related to glutamatergic neurotransmission, such as GRIA1, which might be of crucial importance for transcriptional impairments underlying druginduced striatal synaptic plasticity.
Small-Molecule Bromodomain Inhibitor JQ1 Decreases Heroin Self-administration and Drug-Seeking Behavior
To establish the basis for follow-up in vivo behavioral studies, we next wanted to determine whether long-term heroin exposure induces similar histone H3 hyperacetylation in a rodent model. Adult male Long-Evans rats were trained to selfadminister heroin and were killed 1 or 24 hours after the last Pearson correlations between (A) panacetylated histone H3 (pan-AcH3) and GRIA1 messenger RNA (mRNA) levels, r 5 .07, p 5 .4837, n 5 12 for controls, and n 5 27 for heroin users; and (B) lysine-27 acetylated histone H3 (H3K27ac) and GRIA1 mRNA levels, r 5 .04, p 5 .8900, n 5 12 for controls, and n 5 23 for heroin users. (C, D) Chromatin immunoprecipitation experiments show enrichment of (C) panAcH3 (n 5 13 in the control group and n 5 30 in the heroin group) and (D) H3K27ac (n 5 10 in the control group and n 5 25 in the heroin group) along the GRIA1 gene. Data are represented as mean 6 SEM. Independent Student t tests, *p , .05. (E, F) Transposaseaccessible chromatin with highthroughput sequencing (ATAC-seq) tracks show chromatin accessibility along the human GRIA1 gene at (E) 3 kb upstream and (F) 165 kb downstream of the transcription start site (TSS). Lines represent means, n 5 10 in both groups.
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Biological Psychiatry April 1, 2017; 81:585-594 www.sobp.org/journalself-administration session. We first assayed global pan-AcH3 levels in the rat dorsal striatum using Western blot. Total heroin intake 24 hours after the last self-administration session was used to approximate long-term drug-related effects (a proxy for years of previous heroin use in humans) and lastsession heroin intake 1 hour after the last self-administration session to model acute toxicology (a proxy for urine morphine levels in humans). Although not statistically significant, panAcH3 level tended to be positively correlated with total heroin intake (r 5 .52, p 5 .0847; Figure S5A in Supplement 1) and, with regard to last session heroin intake, was directionally similar to the findings in humans (r 5 2.46, p 5 .3013; Figure  S5B in Supplement 1), indicating that the opposite relationship of long-term and acute heroin exposure on histone H3 acetylation observed in humans might also to some extent be present in rodents. Next, we determined pan-AcH3 and H3K27ac enrichment directly at regions of the rat Gria1 gene corresponding to those assayed in humans using ChIP PCR. Strikingly, we found perfectly analogous heroin-related epigenetic impairments in the two species: a significant increase in the enrichment of pan-AcH3 3 kb upstream and 2 kb downstream of the TSS ( Figure 4A ) and of H3K27ac in the intragenic region ( Figure 4B ). Importantly, these data together suggest that heroin-related hyperacetylation at glutamatergic genes is conserved between humans and rats.
To assess the functional behavioral relevance of heroininduced histone H3 hyperacetylation in vivo, we evaluated in the rodent model the effects of pharmacologically manipulating bromodomains, which specifically recognize acetylated lysine residues and are increasingly being developed as epigenetic therapeutic targets. We implanted guide cannulae bilaterally into the rostral dorsal striatum of adult male LongEvans rats previously trained to self-administer heroin, and on two consecutive days, delivered 20 μmol/L of the smallmolecule bromodomain inhibitor JQ1 5 minutes before selfadministration sessions. We hypothesized that by blocking the functional readout of heroin-induced histone H3 hyperacetylation, we might be able to inhibit self-administration behavior. JQ1-treated animals exhibited a significantly lower number of active lever presses as compared with vehicle-treated rats on both days of testing (53% of control, p 5 .0165 and 36% of control, p 5 .0083 on the first and second day, respectively; Figure 4C ). Strikingly, the effects of JQ1 were long lasting and could still be observed 24 hours (71% of control, p 5 .0722) and 48 hours (50% of control, p 5 .0179) after the last drug delivery. The effect was no longer evident at 96 hours (85% of control, p 5 .4045) ( Figure 4C ). Importantly, JQ1 did not affect inactive lever pressing or general locomotor behavior, emphasizing the specificity of the JQ1 effects to goal-directed behavior ( Figure S6A , B in Supplement 1). We then sought Histone Acetylation Impairments in Human Heroin Users to determine whether JQ1 also affects cue-induced drugseeking behavior. After 1 week of abstinence, animals were injected with 20 μmol/L of JQ1 through the dorsal striatal guide cannulae 5 minutes before a nonreinforced drug-seeking session (60 minutes). JQ1-treated animals showed significantly decreased active lever pressing (42% of control, p 5 .0112) compared with vehicle rats and strikingly, exhibited essentially no drug-seeking behavior in the last 20 minutes of testing ( Figure 4D) . A two-way analysis of variance revealed significant group (F 1,117 5 36.31, p , .0001) and time (F 12,117 5 7.811, p , .0001) effects ( Figure 4D ). Similarly to the previous JQ1 test sessions, inactive lever pressing and general locomotor behavior were not affected by JQ1 ( Figure S6C , D in Supplement 1).
Taken together, our in vivo data indicate that blocking the readout of heroin-related histone H3 hyperacetylation by bromodomain inhibition in self-administering rats reverses addiction-related behavior and strongly support the functional importance of the observed heroin-related epigenetic and transcriptional impairments.
DISCUSSION
Our translational study revealed marked epigenetic and transcriptional impairments in long-term human heroin users related to abnormal histone acetylation and glutamatergic dysregulation. Using evidence from direct interrogation of the human brain, we show that heroin use is associated with hyperacetylation of histone H3 at specific lysine residues (K27 and K23) at discrete genomic locations (GRIA1 and other genes related to glutamatergic synaptic plasticity). Importantly, these epigenetic impairments were associated with alterations in chromatin accessibility and might play an important role in addiction behavior. Furthermore, our data identify the small-molecule bromodomain inhibitor JQ1 as a promising candidate for clinical studies because it potently inhibited heroin self-administration and drug-seeking behaviors in the translational rat model. Glutamatergic input to the striatum has long been implicated in opiate addiction (15, 18) and has been shown to play a critical role in context-induced heroin-seeking and relapserelated behaviors (19) . The AMPA glutamate receptor subunit Gria1 specifically has been implicated in substance use (14, 15, 20, 21) and related neuropsychiatric disorders (17) . Our data now provide new insight highlighting the important contribution of specific acetylation disturbances related to transcriptional alterations of striatal GRIA1 in human heroin abusers that is dynamically regulated with repeated use of the drug. Intriguingly, we had previously documented marked impairments of GRIA1 in heroin-related plasticity at glutamatergic synapses in the human amygdala (16) . Whether histone H3 hyperacetylation is also involved in the regulation of glutamatergic synaptic plasticity in the amygdala and other brain regions remains to be established.
Disturbances of epigenetic mechanisms including histone H3 acetylation are increasingly being recognized to play a crucial role in the development and maintenance of addictive disorders (22) (23) (24) . In particular, hyperacetylation of histone H3 was observed in the promoter region of several genes in the NAc that are induced by repeated cocaine exposure (25) .
In addition, long-term cocaine exposure was shown to disrupt Hdac5 function in the NAc, leading to hyperacetylation and enhanced transcription of Hdac5 target genes (26) . Intriguingly, simultaneous acetylation and phosphorylation of histone H3 in the NAc of rats was shown to be critical for heroininduced conditioned place preference (27) . The current study provides the first direct evidence of opiate-related epigenetic impairments in the human brain, emphasizing that the acetylation disturbance particularly associated with drug use history is rather restricted to the K27 region of the histone H3 tail. In addition, our analogous findings from heroin self-administering rats strongly suggest the translational nature of drug-related impairments in histone acetylation. Acetylation of H3K27 has been shown to activate transcription (28) , inhibit polycomb silencing (29) (30) (31) , and be sensitive to stress (32) . However, nothing is known about its function in the brain or in relation to substance use disorders. In addition, this mark is usually studied in the context of enhancers (33) (34) (35) and superenhancers (36) (37) (38) , whereas its functional role in intragenic regions remains elusive. Even less is known about H3K23ac (39, 40) , for which a group difference was noted for heroin, but the levels did not relate to drug history or acute use as they did for H3K27ac. As such, H3K27ac appears to be more dynamically sensitive to the heroin experience, with acute drug use temporarily reversing the long-term "poised" state of elevated H3K27ac. Interestingly, stress-induced modifications of synaptic plasticity have been shown to be mediated by dynamic epigenetic regulation of glutamatergic genes driven by H3K27ac (32) .
A surprising finding in both human addicts and the rat model currently studied was that heroin-related hyperacetylation was most pronounced within the gene body of GRIA1. Acetylation of the gene body is thought to positively regulate transcriptional elongation by achieving an open chromatin structure that facilitates the passage of RNA polymerase II (41) (42) (43) (44) (45) . In addition, dynamic gene body acetylation plays a critical role in cotranscriptional splicing (46) and regulates the incorporation of histone variants (47, 48) . However, diseasespecific disturbances of gene body acetylation, particularly in the brain, have not been reported to date. Importantly, we also provide direct evidence for a more open state of chromatin across the GRIA1 gene specifically in neurons that overlapped the differentially H3K27ac regions by using ATAC (49) (50) (51) . Our data strongly support a functional role for the heroin-related gene body hyperacetylation with respect to enhanced transcriptional activity of glutamatergic genes in striatal neurons.
An important goal of the study was to evaluate strategies based on our molecular findings that could provide insights for potential clinical treatments. Manipulating acetylation state in various diseases has been attempted mainly with HDAC inhibitors, but such strategies have not proved to be clinically effective because although generally tolerated in patients with cancer, the side-effect profiles will likely be prohibitive for psychiatric clinical applications (52) . Bromodomains (53) specifically recognize acetylated lysine residues, and inhibitors (54) of these protein modules can be used to block the functional readout of acetylated histones and appear to be clinically tolerated by patients (55) . Recently, JQ1 has been shown to inhibit transcriptional responses that occur during memory formation (56), which might be important for Histone Acetylation Impairments in Human Heroin Users Biological Psychiatry April 1, 2017; 81:585-594 www.sobp.org/journalmechanisms implicated in addiction and extinction learning. In addition, JQ1 attenuated the rewarding effect of cocaine in rats by interfering with drug-induced plasticity in the NAc (57) . In the cocaine study, JQ1 was administered during the acquisition phase of conditioned place preference (57) . Here, we show that bromodomain inhibitors effectively decrease drug self-administration behavior. Importantly, JQ1 potently reversed addiction behavior during the maintenance phase and during reinstatement after abstinence in our model, suggesting that this drug might hold clinical promise for the treatment of long-term human heroin users. Importantly, phase 1 clinical trials using JQ1 are ongoing in patients with cancer and serious side effects have not yet been reported (58, 59) , which would set the stage for future clinical addiction studies.
It is important to note that lysine acetylation is not a histone-specific phenomenon and plays an important role in the posttranscriptional regulation of, for example, several transcription factors (e.g., p53, YY1, STAT3), nuclear receptors (e.g., androgen and estrogen receptor), and α-tubulin and Hsp90 (60) . Off-target effects of JQ1 and other bromodomain inhibitors are thus likely to occur and will need to be addressed. Another important caveat of the current study is that most of our biochemical analyses were restricted to the putamen. Although the low abundance of available NAc tissue is prohibitive for many applications, a comparative study of NAc and dorsal striatal epigenetic disturbances is warranted considering the complex roles that distinct striatal regions play in regulating addiction behavior as part of a limbic/cognitive/ motor interface (13, 61) . Similarly, the striatum consists of anatomically, biochemically, and functionally distinct cell populations that have different roles in reinstatement (62) and could be differentially affected by heroin. Addressing cell heterogeneity will provide significant further insights into the complex landscape of heroin-induced histone acetylation impairments in the striatum.
Limitations inherent to working with postmortem human subjects clearly apply to our study and are thus important to note. The severity of drug use, manner of death, suicidal intention of overdose, undocumented drug use, and psychiatric history are difficult to address conclusively. Nonetheless, that significant group effects were observed and replicated in the animal model emphasizes that our neurobiological findings relate to heroin use.
Overall, the current study demonstrates that the history of heroin use determines the degree of histone acetylation at specific lysine residues of the histone tail that links directly to impairments of glutamatergic genes involved in the regulation of synaptic plasticity in the striatum of human heroin users, establishing a pathological state that contributes to the continued cycles of drug-seeking behavior and relapse. Our behavioral data demonstrate the strong potential of bromodomain inhibitors in the treatment of substance use disorders and provide a foundation for follow-up clinical studies targeting epigenetic modifications.
